RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sarepta Therapeutics Stock

Sarepta Therapeutics Debt 2025

Sarepta Therapeutics Debt

34.11 USD

Ticker

SRPT

ISIN

US8036071004

WKN

A1J1BH

In 2025, Sarepta Therapeutics's total debt was 34.11 USD, a -95.79% change from the 809.57 USD total debt recorded in the previous year.

Sarepta Therapeutics Aktienanalyse

What does Sarepta Therapeutics do?

Sarepta Therapeutics Inc is a biopharmaceutical company that was founded in 1980 in Cambridge, Massachusetts, USA. The company focuses on developing therapies for the treatment of rare genetic diseases, particularly muscular dystrophies. Sarepta's mission is to change the lives of patients with rare diseases by developing innovative therapies that can improve their lives. Business model: Sarepta Therapeutics has developed a successful business model in recent years, focusing on the development of innovative therapies for rare diseases. The company utilizes the latest research methods to develop tailored solutions based on the genetic basis of each disease. Various divisions: The various divisions of Sarepta Therapeutics are typically focused on the different diseases against which the company is developing therapies. The portfolio includes products and therapies for: - Duchenne muscular dystrophy - Limb-girdle muscular dystrophy - Congenital myotonic dystrophy - Pompe disease Products: Sarepta has several products on the market to treat patients with various genetic diseases. One of the most well-known products is Exondys 51, used for the treatment of Duchenne muscular dystrophy (DMD). Sarepta has also launched another DMD therapy called Vyondys 53, which is based on a different genetic mutation. In addition to these products, Sarepta has also conducted several clinical studies to test the effectiveness of therapies against other rare genetic diseases such as spinal muscular atrophy, FMlP deficiency, and others. Sarepta Therapeutics has made significant progress in recent years in the development of therapies for rare genetic diseases. The goal is to improve the lives of patients around the world by developing innovative therapies tailored to a genetic basis. Sarepta Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Sarepta Therapeutics's Debt Structure

Sarepta Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Sarepta Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Sarepta Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Sarepta Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Sarepta Therapeutics stock

What is the debt of Sarepta Therapeutics this year?

Sarepta Therapeutics has a debt level of 34.11 USD this year.

What was the debt of Sarepta Therapeutics compared to the previous year?

The debt of Sarepta Therapeutics has increased by -95.79% compared to the previous year dropped.

What are the consequences of high debt for investors in Sarepta Therapeutics?

High debt can pose a risk for investors of Sarepta Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Sarepta Therapeutics?

Low debt means that Sarepta Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Sarepta Therapeutics affect the company?

An increase in debt of Sarepta Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Sarepta Therapeutics affect the company?

A reduction in debt of Sarepta Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Sarepta Therapeutics?

Some factors that can influence the debt of Sarepta Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Sarepta Therapeutics so important for investors?

The debts of Sarepta Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Sarepta Therapeutics take to change the debt?

To change the debt, Sarepta Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Sarepta Therapeutics pay?

Over the past 12 months, Sarepta Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sarepta Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Sarepta Therapeutics?

The current dividend yield of Sarepta Therapeutics is .

When does Sarepta Therapeutics pay dividends?

Sarepta Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sarepta Therapeutics?

Sarepta Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Sarepta Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sarepta Therapeutics located?

Sarepta Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sarepta Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sarepta Therapeutics from 8/6/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/6/2025.

When did Sarepta Therapeutics pay the last dividend?

The last dividend was paid out on 8/6/2025.

What was the dividend of Sarepta Therapeutics in the year 2024?

In the year 2024, Sarepta Therapeutics distributed 0 USD as dividends.

In which currency does Sarepta Therapeutics pay out the dividend?

The dividends of Sarepta Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sarepta Therapeutics

Our stock analysis for Sarepta Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sarepta Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.